Multiple Myeloma | Specialty

Dr. Voorhees on the ELOQUENT-3 Trial in Late Relapsed/Refractory Multiple Myeloma

September 12th 2019

Peter Voorhees, MD, physician, Levine Cancer Institute, Atrium Health, discusses the randomized phase II ELOQUENT-3 trial in relapsed/refractory multiple myeloma.

Dr. Krishnan on Key Aspects of the ELOQUENT Trials in Relapsed/Refractory Multiple Myeloma

September 11th 2019

Amrita Krishnan, MD, director of the Judy and Bernard Briskin Center for Multiple Myeloma Research and a professor in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope, discusses key aspects of the phase III ELOQUENT-2 and -3 trials in relapsed/refractory multiple myeloma.

Dr. Larson on Potentially Practice-Changing Data in Frontline Multiple Myeloma

September 6th 2019

Sarah M. Larson, MD, discusses potentially practice-changing studies for patients with transplant-eligible and -ineligible multiple myeloma.

Encouraging Data Advance Research in Relapsed/Refractory Myeloma

September 5th 2019

Amrita Krishnan, MD, highlights recent research in relapsed/refractory multiple myeloma.

Mapping Multiple Myeloma Advances in NYC

September 4th 2019

We traveled to New York City, New York, for a State of the Science Summit™ on Multiple Myeloma, which featured insights from the faculty from the Mount Sinai Hospital.

Novel Frontline Approaches Induce Deep, Durable Responses in Multiple Myeloma

September 3rd 2019

Michael A. Rosenzweig, MD, MS, discusses changes in the frontline setting of multiple myeloma.

Dr. Moreau on the CASSIOPEIA Trial in Transplant-Eligible Myeloma

August 30th 2019

Phillippe Moreau, MD, head, Hematology Department, university professor of clinical hematology, University Hospital of Nantes, France, discusses the phase III CASSIOPEIA trial in transplant-eligible multiple myeloma.

Genomic Testing Puts Myeloma Paradigm on Personalized Path

August 30th 2019

Samir Parekh, MBBS, highlights ongoing research regarding personalized medicine for multiple myeloma.

Novel Antibody-Based Approaches on Horizon in Multiple Myeloma

August 30th 2019

Hearn Jay Cho, MD, PhD, provides background on these novel approaches, while highlighting exciting trials to look for in the future.

Jagannath Shares Insight on Treatment Strategies in Relapsed/Refractory Myeloma

August 28th 2019

Sundar Jagannath, MD, highlights the current state of the relapsed/refractory multiple myeloma paradigm and research regarding next steps for advancing treatment.

Elotuzumab Triplet Approved in Europe for Multiple Myeloma

August 28th 2019

The European Commission has approved elotuzumab for use in combination with pomalidomide and low-dose dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma following 2 or more prior therapies, including lenalidomide and a proteasome inhibitor.

Dr. Cowan on the Future of Selinexor in Multiple Myeloma

August 23rd 2019

Andrew J. Cowan, MD, an assistant professor of medicine at University of Washington School of Medicine, and hematologist/oncologist at Seattle Cancer Care Alliance, discusses the future of selinexor (Xpovio) in multiple myeloma.

Daratumumab/VMP Combo Approved in Japan for Frontline Myeloma

August 22nd 2019

The Japanese Ministry of Health, Labor and Welfare has approved daratumumab for use in combination with bortezomib, melphalan, and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Published Selinexor Data Show Sustained Survival in Heavily Pretreated Myeloma

August 22nd 2019

Selinexor in combination with twice-weekly dexamethasone led to a median overall survival of 15.6 months in patients with heavily pretreated multiple myeloma who had a minimal response or better to the novel agent compared with 1.7 months in those whose disease progressed or had unevaluable responses.

Preventing Progression and Chasing Cure in Smoldering Myeloma

August 14th 2019

Data from several clinical trials support treatment with lenalidomide (Revlimid) plus low-dose dexamethasone in select patients with high-risk smoldering multiple myeloma to prevent disease progression and other promising combinations under investigation are showing curative potential.

Combinations Mark Future of Immunotherapy in Multiple Myeloma

August 14th 2019

The emergence of monoclonal antibodies, immunomodulatory agents, immunotoxins, bispecific T-cell engagers, and CAR T-cell therapies will redefine multiple myeloma treatment. However, these new approaches, by themselves, are not enough to achieve cure; they must be used in combination.

Dr. Rodriguez on Evolving Role of Small Molecules in Multiple Myeloma

August 14th 2019

Cesar Rodriguez Valdes, MD, assistant professor of Hematology and Oncology, Wake Forest University Comprehensive Cancer Center, highlights the evolving role of small molecules in multiple myeloma.

Multiagent Regimens Continue to Spearhead Progress in Late Relapsed Myeloma

August 14th 2019

Peter Voorhees, MD, discusses the recent data with triplet regimens in late relapsed multiple myeloma and other novel agents shaking up the paradigm.

Novel Induction Regimens Boost Survival in Newly Diagnosed Myeloma

August 13th 2019

The goal of induction regimens for patients with newly diagnosed multiple myeloma is to reduce the burden of disease and prolong durability of response and overall survival, while minimizing toxicity.

Identifying Patients and Treating With CAR T-Cell Therapy

August 13th 2019